Early clinical signs, triggering agents, time to onset of reaction, mortality and methods of treatment were identified in 123 suspected malignant hyperthermia reactions. In vitro contracture test results were compared with clinical signs and the Malignant Hyperthermia Clinical Grading Scale. Increased end-tidal carbon dioxide is the earliest sign when not preceded by masseter spasm. Earlier diagnosis reduces the incidence of rigidity and severe metabolic acidosis. The combination of suxamethonium and a potent volatile anaesthetic agent triggers an earlier reaction compared with a volatile agent alone. There has been zero mortality since 1981, essentially due to a combination of advanced monitoring capability, increased anaesthetist awareness of malignant hyperthermia, and dantrolene availability.
Malignant hyperthermia (MH) is an uncommon pharmaco-genetic disorder of skeletal muscle first described by Denborough and Lovell in 1960 1 . It has autosomal dominant inheritance with an incidence of approximately 1:40,000 anaesthetics administered in adults, and 1:15,000 in children.
This paper reviews reported suspected MH reactions during operative procedures between 1968, when the first case in New Zealand was clinically identified, and 2001. Early clinical signs, triggering agents, time to onset, mortality and methods of treatment are identified. The paper aims to compare the in vitro contracture test (IVCT) results with observed clinical signs, especially those occurring earliest in the course of the reaction. It also compares IVCT results with the independently derived Malignant Hyperthermia Clinical Grading Scale (MHCGS) 2 devised to improve MH susceptibility prediction. All patients were tested at Palmerston North, the centre for MH susceptibility testing in New Zealand.
METHODS
Patients were identified from the Palmerston North Hospital MH database where information on suspected MH reactions throughout the country is recorded. Cases where a presumptive diagnosis of malignant hyperthermia had resulted in specific action during an anaesthetic or in the immediate postoperative period were included.
Three groups were defined according to IVCT findings: MH Susceptible (MHS), MH Equivocal (MHE) and MH Normal (MHN). In vitro contracture testing was conducted according to the European MH Group Protocol 3 . A diagnosis of MHS is made when contractures equal to or greater than 0.2 g are obtained with 2% halothane and with 2 mmol of caffeine, each with a fresh specimen. Where only one test is positive, the diagnosis is MHE.
With contractures to both agents less than 0.2 g, a negative or MHN result is obtained.
The MHS group included 20 untested individuals who had had a clinically fulminant MH reaction and 11 of whom had subsequently died. Two of these individuals had a "causative" mutation 4 identified from pathology specimens. Of the surviving nine, a "causative" mutation has been identified in four but IVCT was declined and five others were unable to be tested. All have an immediate relative (parent, sibling, or child) MHS with IVCT.
The likelihood that the reaction during anaesthesia was MH was retrospectively assigned to each member of the three groups using the MH clinical grading scale ( Table 2 ) from data documented in clinical records.
One hundred and twenty-three suspected cases from 109 separate families were considered for analysis. Excluded were 14 children (optimum age for biopsy is >10 years) and two adults awaiting IVCT, and a further fourteen adults who had declined testing or been lost to follow-up. A total of 93 cases investigated by IVCT remained for analysis.
RESULTS
An MH susceptible diagnosis was made in 53 cases (52 individuals). A further 12 were classified as MHE and 28 MHN. The groups were 65-75% male and the median age at the time of suspected reaction was 18 years (6 months to 57 years). Forty-seven per cent of the MHS group, 25% of the MHE group and 12% of the MHN group identified themselves as New Zealand Maori (14% of New Zealand population). Table 1 indicates the observed earliest clinical signs in a suspected MH reaction for each diagnostic group. End-tidal CO 2 (EtCO 2 ) monitoring was routinely available for the majority of operating theatre anaesthetists by 1991. Raised EtCO 2 (>55 mmHg controlled ventilation, >60 mmHg spontaneous ventilation) 2 was the first observed clinical sign in 70% of suspected reactions subsequently diagnosed MHS between 1991 and 2001 (Table 1 ). This developed with controlled ventilation in 7/11 and EtCO 2 was generally >79 mmHg in the remaining four with spontaneous ventilation (maximum measurement 107 mmHg). Increased EtCO 2 was the first abnormal sign in 3/10 patients who were MHN although two were breathing spontaneously with EtCO 2 readings <70 mmHg.
Clinical Signs
Masseter spasm at induction was the first presenting sign in 22/93 and all episodes were associated with the use of suxamethonium. In all, 15/22 patients subsequently tested MHS (see Discussion). Masseter spasm was the only abnormal sign in two (4%) MHS patients and three (8%) from the other groups.
Tachycardia (>100 bpm) was present in 95% of patients in the MHS group. Although tachycardia was the most common earliest sign before EtCO 2 monitoring became available (Table 1) it was the earliest sign in only 1/16 following the introduction of EtCO 2 monitoring. Arrhythmias, particularly ventricular ectopics were the earliest sign in 3/53 reactions, but were present at some stage in 15/53 (30%). Tachycardia was less common in the MHE and MHN groups and arrhythmias were not reported in either of these groups.
Increased temperatures ranged from 37.1°C to 43°C in the MHS group. Two subgroups were identified; (a) a rapidly fulminant group where temperature increase closely followed increased EtCO 2 and tachycardia (28/53), and (b) a less reactive group with lower more slowly increasing temperatures (<38.5°C) even in the presence of hypermetabolism (25/53). There was a wide range of temperature recordings in both the MHE (36.8°C to 42°C) and the MHN (36.9°C to 40.5°C) groups. Thirteen of 28 (13/28) MHN patients had pyrexia as the earliest sign five had pyrexia as the only sign.
Low SpO 2 (<95%) was the first abnormal sign in only one of 26 MHS patients (measurements were recorded in 26 patients with the availability of SpO 2 from 1987) although the measurement was abnormal at some point in the reaction in 10/26. Low SpO 2 recordings were only very occasionally found in patients with MHE and MHN diagnoses.
Acid/base measurements were conducted in 50% 
The first clinical sign has been defined as the sign that caused the anaesthetist to consider MH as a possible diagnosis.
of MHS reactions. Eleven of 27 (11/27) had a moderate to severe acid base deficit (>8 mmol/l). Only one of five (MHE) and one of nine (MHN) had a significant metabolic acidosis. Generalized body rigidity was noted in 16/ 53 MHS patients, and in all but two was associated with suxamethonium. In the majority rigidity developed after 30 minutes but in three of 16 was present within 10 minutes of induction. Two of 13 in the MHE group and three of 28 in the MHN group were also reported to develop rigidity. Cyanosis, flushing, disseminated intravascular coagulation, and severe hyperkalaemia (>7 mmol/l) occurred infrequently. Creatine kinase (CK) increase generally peaked after 24 hours in the MHS group (maximum measurement 165,300 IU). No patient in the MHE or MHN groups exceeded a CK measurement of 15,000 IU.
Triggering Agents
Suxamethonium alone was the triggering agent in one MHS patient. Twelve patients received a volatile agent only ( Figure 1 ). One patient was treated for an MH reaction in the absence of triggering agents and has been the subject of a previous report 5 . There was insufficient information in two patients. The remaining 37 patients received both suxamethonium and a volatile agent. Halothane and isoflurane were the only triggering potent inhalational agents used although sevoflurane is likely to have caused a reaction in a young child yet to be tested.
Time to onset of the reaction (defined as anaesthetist discontinuing volatile agents) is shown in Figure 1 : 12/37 (32%) reacted within 15 minutes of induction and a further eight within 30 minutes with a suxamethonium/volatile agent combination. In three patients the onset with this combination was considerably delayed. The onset time with inhalational agents alone peaked at 30 minutes although one case particularly triggered very late. All but one of the MHE group developed signs within 30 minutes of induction.
Suspected clinical reactions were reported from a wide range of surgical specialties. Orthopaedic surgery predominated. The majority of procedures were elective in all groups.
MHCGS
A trend is apparent in Table 2 where all available MHCGS ranks are compared to IVCT diagnostic groups. MHS patients tended to rank higher than MHN but there is no absolute cut-off point.
Treatment and Mortality
Active cooling (ice or IV fluid) was employed in 44% of the MHS group, 8.6% of the MHE group, and 16% of the MHN group. Dantrolene sodium (dantrolene) was given to 24% of the MHS group, 0% of MHE group patients and to 16% of the MHN group. An initial dose of 1.5 to 2 mg/kg was used and maximum dose administered 17 mg/kg over a 36-hour period. Other specific treatments recorded include bicarbonate and procainamide.
Mortality was 21% (11 patients, all before 1981) for the MHS group. There were no recorded deaths in either the MHE or MHN groups.
DISCUSSION
Patients in the Palmerston North MH database were entered following referral by anaesthetists and other medical practitioners, from information received from known MH susceptible families, from referrals made to the Medic Alert Foundation following adverse anaesthetic events and data obtained from coroners' reports held at National Archives of New Zealand. As reporting of suspected MH reactions remains informal, an unspecified number of MH reactions may have been omitted.
There are inherent difficulties in collecting retrospective medical data over a thirty-three year period including incomplete, uninterpretable or lost records, particularly the earlier records. Conclusions have been inferred on the basis of apparent trends rather than by formal statistical methods. Early appropriate treatment reduces mortality and morbidity in an MH reaction and recognition of the presenting clinical signs is paramount. Improvement in monitoring of anaesthesia in the period under review has led to a change in the first clinical sign of MH. Before 1991 tachycardia was the most prominent presenting sign, but with the introduction of EtCO 2 monitoring, 70% of patients first developed an increase in EtCO 2 often evidenced by an increased minute volume to maintain normal EtCO 2 ( Table 1 ). In the four patients experiencing masseter spasm (see below), trigger agents were discontinued only when increasing EtCO 2 as the next developing sign gave further confirmation of an MH reaction. This is consistent with research demonstrating that EtCO 2 increases initially followed by tachycardia and in a classical MH reaction, within minutes by an increase in temperature 6, 7 .
Of patients investigated with a negative contracture test, three out of 10 had an increased EtCO 2 as the first abnormal sign, which suggests hypercarbia should be carefully evaluated before considering the possibility of an MH reaction. Hypoventilation, sepsis, light anaesthesia, an inaccurate monitor, machine and ventilator or circuit dysfunction, and very rarely thyroid storm 8 need to be considered with persistent elevated EtCO 2 .
Tachycardia secondary to increased metabolism and sympathetic stimulation is an early sign of MH 6 . However in this series it was the first clinical sign in only one out of 16 patients when EtCO 2 monitoring was used.
Masseter spasm was severe enough to cause difficulty with intubation and volatile agents were continued in all 22 patients. Fifteen of these were subsequently diagnosed MHS on IVCT. In six of this group, the surgical procedures had to be abandoned within 25 minutes of induction because of increasing signs of hypermetabolism. Anaesthesia was continued in the remaining patients, most of whom had other mild signs of hypermetabolism and were later referred for investigation for possible MH. The fulminant reactions indicate that early consideration should be given to discontinuing the anaesthetic or changing to a non-triggering anaesthetic technique if masseter spasm develops at induction of anaesthesia 9, 10 . Only four of 22 with masseter spasm had negative muscle biopsy results and three MHE, less than other investigating centres, although the total numbers were small which may reflect a declining use of suxamethonium particularly over the last 10 years or more accurate patient assessment.
Five MHN patients were investigated for elevated temperature developing in recovery or later with no other signs. Halsall 11 found that even with significantly high temperatures, postoperative pyrexia alone rarely indicates MH susceptibility confirming the findings in this review. There is no evidence that a patient with stable vital signs on discharge from the post anaesthetic recovery room who subsequently develops pyrexia is MH susceptible.
Desaturation was rarely observed as a first abnormal sign 12 in this series and was abnormal in only 38% of reactions. Although oxygen consumption can increase, threefold, increased FiO 2 presumably limits changes.
Prominent signs from previous decades have been less apparent over the last 10 to 15 years. Improved monitoring and awareness and hence early diagnosis have reduced the incidence of severe metabolic acidosis, which in the early stages is limited by hepatic uptake of lactic acid 13 . Similarly, generalized body rigidity was reported in only 30% although it can appear relatively early in a reaction.
Depolarizing muscle relaxants and volatile anaesthetic agents are potential triggering agents in susceptible individuals. There have been no documented MH deaths from suxamethonium alone, although this does occur in susceptible swine 7, 14 . Halothane and isoflurane were the only volatile agent triggers in this review. However all potent inhalational agents have been implicated [15] [16] [17] .
One patient had a probable MH episode in the absence of trigger agents 5 . His mother died from an MH reaction, he had had a previous reaction, a very strongly positive IVCT and a causative mutation (T4826I) has been demonstrated in this individual. Recent research has demonstrated positive IVCTs and "causative" mutations in a group of individuals with exercise-induced rhabdomyolysis [18] [19] [20] implicating stress as a likely triggering factor.
The onset time of MH reactions in the MHS group (Figure 1) for either volatile agent alone or volatile agent in combination with suxamethonium confirms previous reports 21 . The combination of suxamethonium with a volatile agent in general causes a more rapid onset time in susceptible individuals (Figure 1 ). This indicates a synergistic effect 22 , suggesting that both agents contribute to the underlying mechanism of malignant hyperthermia; that is, increased calcium release from the sarcoplasmic reticulum 23 . Three cases associated with suxamethonium at induction had delayed triggering. Genetic predisposition, specific volatile agent, dose, use of barbiturates and hypothermia may contribute to a delayed onset 24 . No fatal reaction has been reported in New Zealand for 20 years but one surviving patient required repeated cardioversion for sustained ventricular tachycardia and at least two others required inotropic support for cardiovascular collapse.
New Zealand Maori (approximately 14% of N.Z. population) are over-represented in both the MHS and MHE groups reflecting the existence of one very large susceptible Maori family 25 . An increased incidence of males in all groups is in keeping with international statistics reflecting high skeletal muscle bulk.
Geographic distribution of suspected MH reactions is indicated in Figure 2 . Disproportionate representation relative to regional population size may exist in part due to distribution of the extended Maori family. While most regions have yielded a mixture of MHS, MHE and MHN IVCT results, two regions have produced only MHS IVCT results, suggesting either astute patient selection or some clinically suspicious reactions have been overlooked as some negative results would be expected if all suspected reactions are investigated. Suspected MH reactions in New Zealand are uncommon ( Figure 3 ) and confirmed reactions average only one or two per annum (population 3.5 million).
Reporting of clinically suspicious cases appears to have increased during the late 1980s and into the early 1990s ( Figure 3 ). Anaesthetist awareness of MH and improved patient monitoring have contributed. From the mid nineties onward there appears to be a decrease in incidence of MH reactions (Figure 3) , probably related to an increase in the use of total intravenous anaesthesia (TIVA), the decline in use of suxamethonium and halothane (considered the most potent trigger of MH), and better identification of families and susceptible individuals.
Early management of an MH reaction involves prompt recognition, removal of the triggering agent, administration of 100% oxygen, hyperventilation to remove carbon dioxide and volatile agents, active cooling and intravenous dantrolene injected at 10 to 15 minute intervals until the MH reaction has resolved.
Dantrolene was first registered for use in New Zealand in September 1981 (personal communication-Pharmacia Limited 1982 were treated appropriately, while none of the MHE group received dantrolene. Interestingly, 22% of the MHN group were given dantrolene. Dantrolene sodium should not be used sparingly. Its principal side-effects are gastrointestinal symptoms, phlebitis and muscular weakness, and although this may also affect the respiratory muscles the onset is slow and can be managed without difficulty. Together with increased awareness of MH and improved monitoring, dantrolene has been responsible for reducing the mortality of this disorder from 80% to less than 5%.
In the initial treatment studies of MH reactions with dantrolene sodium, Kolb 26 found a mean dose of 2.5 mg/kg treated the reaction effectively. Larach 27 subsequently found that patients with probable MH events (MHCGS =>4) required a mean initial dose of 2.3 mg/kg and research on awake volunteers found that maximum twitch depression occurs with a dose of 2.4 mg/kg 28 . An initial dose of 2.5 mg/kg repeated every 10 to 15 minutes until control of the reaction is obtained is now recommended 29 . It is advisable to use appropriate doses as recrudescence has been associated with fatality 27 .
The Proctor and Gamble data sheet advises a maximum dose of 10 mg/kg 30 . This was based on the non-scientific studies of Harrison and Kolb who found that the above dose could be used with safety (Harrison GG, personal communication). It has been used in doses of more than fourfold indicating that as much dantrolene as necessary should be administered 31 .
The MH Clinical Grading Scale (MHCGS) was devised to improve MH susceptibility prediction as all indicators of MH are non-specific and a clear clinical definition of MH is lacking. The MHCGS is an ordinal six-point grading scale which ranks MH likelihood independent of contracture results to determine likelihood that a reported adverse anaesthetic event was an MH event. A "raw" score is produced which is translated into MH ranks (rank 1=almost never, rank 6=almost certain MH) 2 .
In this review a trend is apparent with MHS patients achieving higher rankings and MHN lower rankings but there is no precise cut-off point. In the MHS group the diagnosis was sometimes achieved early in the reaction before all clinical indicators had developed thereby skewing the findings towards the lower rankings (2+3). In other reactions insufficient recording of data influenced ranking. Two MHN cases achieved rank 5 and one MHN case ranked 6 although the latter had coexistent sepsis. False negative diagnoses are unlikely. There are only 11 reports in the anaesthetic literature [32] [33] [34] and all but one 35 or possibly two 36 could have an alternative cause such as coexistent myopathy, sepsis or a non-standard method of testing. The above three cases were all well documented and monitored anaesthetic events and serve as cautions against the use of the grading scale as an absolute comparison between centres. These findings are also consistent with other research 37 that the MHCGS cannot replace the IVCT and is not precise enough to decide if an individual should undergo muscle biopsy. No definite causes for the metabolic changes were apparent in the MHN group. Light microscopy in all, and histochemistry in some patients was undertaken. Exclusion of malignant hyperthermia was the principal reason for testing.
The MHE category represents a "grey" area under permanent review and some MHE diagnoses most likely are normal variants 38 . This group contains both true positive and true negative results 39 of replacing IVCT with a DNA-based test for susceptibility to MH, DNA and RNA samples from families with MHS members have been used for genetic screening. As a causative factor in MH, the ryanodine receptor gene (RYR1) has been the most widely studied and to date 15 mutations in the RYR1 gene which result in altered amino acid residues in the skeletal muscle ryanodine receptor have been shown to be causative of MH 41, 42 . Three of the causative mutations (R163C, G341R, G2433R) have been identified in three separate small New Zealand families. Five novel mutations have been identified in an additional six families. These include R2452W, R401C, R2454W 20, 43 and T4826I 25 the latter in a large Maori family. The first three mutations occur in the documented "hot-spot" regions and therefore are likely to be causative of MH. The T4826I mutation occurs in the C-terminal domain of the Ryr 1 protein, a region not previously associated with MH susceptibility. Subsequently three other mutations linked to MH susceptibility have been identified in this region [44] [45] [46] .
With the identification of causative mutations genetic diagnosis of MH susceptibility is now available for several New Zealand families. This approach must be taken with extreme caution because of discordance in susceptible families and also the existence of at least five other genetic loci associated with MH 40 . Currently an MHS diagnosis can be made using family-specific DNA-based tests. This avoids the need for IVCT in an individual with a confirmed causative mutation and is a significant advance in the investigation of MH. The existence of multiple loci associated with MH, the possibility of multiple mutations in an individual family and the absence of identification of a mutation in a significant number of susceptible MH families requires that any individual testing negative would need confirmation with IVCT.
In summary, this review demonstrates the changing presentation of malignant hyperthermia with earlier diagnosis aided by EtCO 2 monitoring, and less prominence of classical signs such as rigidity and severe metabolic acidosis. The relative safety of dantrolene suggests it should be used earlier rather than withheld if signs of MH are present. While DNA analysis will provide diagnosis in some families IVCT at present remains the "gold standard" for investigating susceptibility to MH.
